RealityRewi.red

Synchron paused its brain implant trials over a cable. Some volunteers already have it

The company that sold itself as the cautious alternative to Neuralink has stopped enrolling patients, is cutting jobs in New York, and is hiring in San Diego for a device that abandons its signature idea.

Reality Admin//Nov 12, 2026//4 MIN READ
Synchron paused its brain implant trials over a cable. Some volunteers already have it

Synchron's sales pitch has always been that it is the careful one. Neuralink drills a hole in your skull and threads wires into your brain. Synchron slides a mesh tube up through the jugular vein and parks it in a blood vessel over the motor cortex, no brain surgery required. Investors liked that.

This week the careful one hit the brakes. WIRED's Emily Mullin reported on Thursday that Synchron has paused enrollment in the clinical trials of its second-generation implant after the device failed to perform as expected in the first people to receive it.

The company confirmed the pause and named the culprit. In a statement to WIRED, Synchron said it stopped enrolling "after identifying a performance issue involving the lead, the cable that carries signals from the Stentrode to the implanted electronics."

What broke, and what Synchron says didn't

The Stentrode is the sensor. It sits in the vessel and listens to the brain. The lead is the wire that carries what it hears down to the electronics implanted in the body. If the wire underperforms, it doesn't much matter how well the sensor is listening.

Synchron is keen that you keep those two parts separate in your head. "The issue does not involve the Stentrode itself and no safety issues related to the device have been identified. The pause was a company decision, not an FDA-directed action," the statement says.

WIRED reached five of the US trial sites and two confirmed recruitment is on hold. A coordinator at one said the pause was not about safety. The company, the coordinator said, was checking that it is getting the readouts it is looking for.

That is a polite way to describe a brain-computer interface whose signal is not arriving properly. Synchron hasn't said how the lead is failing, how many participants are affected or what the people already implanted can and can't do with the device today.

The people who already have one

That last group is the uncomfortable part. The second-generation trial launched this spring across sites in the US, Australia and Canada, and WIRED reports that some participants have already had the device implanted. They volunteered to have experimental hardware placed in their bodies, and that hardware is now the subject of a redesign.

Synchron's answer is a promise. "We will continue to support participants with Stentrode devices across their lifetime. Our commitment to their care and well-being remains unchanged," it told WIRED.

What it will not do is patch the cable and carry on. The company says it has brought lead design and manufacturing in-house and will upgrade the whole Stentrode system before it enrolls anyone else. It has given no restart date. That makes the people with the current version the only users of a design their maker has already decided to replace.

Fewer jobs in New York, a new team in San Diego

The pause comes with a restructuring. WIRED reports that Synchron is cutting jobs and shrinking its footprint in New York while it builds up a team in San Diego. The company's website and LinkedIn page list around a dozen openings there, for electrical and mechanical engineers, chip designers and materials scientists.

That team will build the upgraded lead and Stentrode. It will also work on a device Synchron has not shown anyone, one its website says will go "beyond the blood vessels altogether." Chief executive Tom Oxley has previously told WIRED he wants hardware that reaches several brain regions at once, for things more complicated than moving a cursor.

Read that again with the company's history in mind. Synchron's whole identity is the blood vessel route. The first-generation Stentrode went into ten volunteers in the US and Australia, who used it to send email, shop and bank online with their thoughts. Now, with the second generation stalled on a cable, the hiring is for something that leaves the blood vessels behind.

Oxley is not conceding anything about the current product. "We still have strong confidence that it has the potential to be a first-line therapy," he told WIRED.

Why a cable can cost years

These trials are the step before the large late-stage study the FDA needs to see before it will let anyone sell a device. Every month Synchron's enrollment stays shut, that bigger study slides, and a redesigned system raises the question of how much of the existing data still counts.

The money can probably wait. Synchron closed a $200 million round last fall at a valuation estimated at close to $1 billion, with backing from Khosla Ventures and the venture firms of Bill Gates and Jeff Bezos. Neuralink, by comparison, was reportedly valued as high as $42 billion in secondary sales this summer.

Neuralink has its own version of this story. In 2024, weeks after Noland Arbaugh became its first volunteer, several of the implant's threads pulled out of his brain and he lost cursor control. The company got it back by rewriting its recording algorithm.

Synchron has picked the slower fix. You can retune software around missing threads. A cable that doesn't carry the signal has to be rebuilt, tested and put into a new set of volunteers. The surgery was supposed to be the hard part. It turned out to be the wiring.

Sources: WIRED, The World of Implantable Devices.

// RELATED_SIGNALS

More from the feed